Free Trial

SI-BONE (SIBN) Stock Price, News & Analysis

+0.59 (+4.01%)
(As of 07/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
533,973 shs
Average Volume
337,395 shs
Market Capitalization
$631.34 million
P/E Ratio
Dividend Yield
Price Target

SI-BONE MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
71.9% Upside
$26.33 Price Target
Short Interest
5.58% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.98mentions of SI-BONE in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$172,555 Sold Last Quarter
Proj. Earnings Growth
From ($0.95) to ($0.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.87 out of 5 stars

Medical Sector

211th out of 917 stocks

Surgical & Medical Instruments Industry

25th out of 101 stocks

SIBN stock logo


SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

SIBN Stock Price History

SIBN Stock News Headlines

Anyone can do this, rich and poor alike
I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.
Anyone can do this, rich and poor alike
I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.
JMP Securities Reaffirms Their Buy Rating on SI-Bone (SIBN)
Piper Sandler Keeps Their Buy Rating on SI-Bone (SIBN)
See More Headlines
Receive SIBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$138.89 million
Book Value
$4.18 per share


Free Float
Market Cap
$631.34 million

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

SIBN Stock Analysis - Frequently Asked Questions

How have SIBN shares performed this year?

SI-BONE's stock was trading at $20.99 at the beginning of 2024. Since then, SIBN stock has decreased by 27.0% and is now trading at $15.32.
View the best growth stocks for 2024 here

How were SI-BONE's earnings last quarter?

SI-BONE, Inc. (NASDAQ:SIBN) posted its quarterly earnings results on Monday, May, 6th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.02. The firm earned $37.87 million during the quarter, compared to analyst estimates of $36.45 million. SI-BONE had a negative net margin of 29.93% and a negative trailing twelve-month return on equity of 25.14%.

What is Jeffrey Dunn's approval rating as SI-BONE's CEO?

10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Does SI-BONE have any subsidiaries?

SI-BONE subsidiaries include these companies: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD.

When did SI-BONE IPO?

SI-BONE (SIBN) raised $84 million in an initial public offering on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who are SI-BONE's major shareholders?

Top institutional investors of SI-BONE include Harbor Capital Advisors Inc. (0.47%). Insiders that own company stock include Laura Francis, Anthony J Recupero, Anshul Maheshwari, Michael A Pisetsky, John Gordon Freund, Timothy E Davis Jr and Mika Nishimura.
View institutional ownership trends

How do I buy shares of SI-BONE?

Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of SI-BONE own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SI-BONE investors own include CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), RTX (RTX), Thermo Fisher Scientific (TMO) and Verizon Communications (VZ).

This page (NASDAQ:SIBN) was last updated on 7/13/2024 by Staff

From Our Partners